Brentuximab Vedotin in Combination With Nivolumab in Relapsed or Refractory Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brentuximab Vedotin in Combination With Nivolumab in Relapsed or Refractory Hodgkin Lymphoma: 3-Year Study Results
Blood 2021 Apr 07;[EPub Ahead of Print], R Advani, AJ Moskowitz, NL Bartlett, J Vose, R Ramchandren, T Feldman, AS LaCasce, B Christian, SM Ansell, CH Moskowitz, L Brown, C Zhang, D Taft, S Ansari, M Sacchi, L Ho, AF HerreraFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.